|
Volumn 19, Issue 8, 2005, Pages 655-657
|
Economic issues in coronary heart disease prevention in India
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ACETYLSALICYLIC ACID;
AMLODIPINE;
ATENOLOL;
ATORVASTATIN;
CLOPIDOGREL;
DILTIAZEM;
ENALAPRIL;
FUROSEMIDE;
GLIBENCLAMIDE;
HYDROCHLOROTHIAZIDE;
LISINOPRIL;
LOSARTAN;
METFORMIN;
METOPROLOL;
NIFEDIPINE;
PERINDOPRIL;
PIOGLITAZONE;
RAMIPRIL;
ROSUVASTATIN;
SIMVASTATIN;
TELMISARTAN;
ARTICLE;
CARDIOVASCULAR RISK;
DRUG COST;
EPIDEMIC;
HEALTH CARE COST;
HEALTH ECONOMICS;
HUMAN;
HYPERTENSION;
INDIA;
ISCHEMIC HEART DISEASE;
LIFESTYLE;
RISK ASSESSMENT;
RISK FACTOR;
WORLD HEALTH ORGANIZATION;
CARDIOVASCULAR AGENTS;
CORONARY DISEASE;
DEVELOPING COUNTRIES;
DRUG COSTS;
HUMANS;
INDIA;
|
EID: 23644446488
PISSN: 09509240
EISSN: None
Source Type: Journal
DOI: 10.1038/sj.jhh.1001871 Document Type: Article |
Times cited : (10)
|
References (12)
|